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UNIT B6.4Contrast Agents
OVERVIEW
Contrast agents in general are exogeneous substances employed to alter natural tissue
contrast. The motivation behind the use of contrast agents in MR imaging is to further
enhance contrast between normal and diseased tissue types and indicate functionality of
an organ. The contrast agents used in nuclear imaging techniques such as positron
emission tomography (PET) and computed tomography (CT) provide a direct effect. On
the other hand, in MR imaging, the effects of contrast agents are indirect and MR signal
is not derived from the contrast agent itself but from its effect on the inherent proton
relaxation times of the tissue in which it resides.
Effects of the contrast agent on relaxation times are expressed in terms of its relaxivities
(K1, K2) in liters per moles per sec (liter/mol/sec) and concentration of contrast agent (C)
in millimoles per liter (mmol/liter):
and
where T1,0 and T2,0 are inherent longitudinal and transverse relaxation times, respectively.
The relaxivity of the contrast agent is defined as the change in relaxation rate per unit
concentration of contrast agent. One application of T1-reducing contrast agents is to
enhance blood vessels (Fig. B6.4.1).
In the healthy brain, the contrast agent cannot cross the blood/brain barrier and the signal
enhancement occurs in the blood itself. In Fig. B6.4.1, it is shown that gray matter is also
slightly enhanced. This is because it contains a small fraction of blood vessels. Another
application of contrast agents is to detect the presence of tumors. Edge enhancement of
tumors is seen because of the vascular content of the tumor. Although several contrast
agents have been frequently used in MRI, currently an exogeneous contrast agent,
Gd-DTPA (gadolinium diethylenetriamine pentaacetic acid) is the only MR contrast agent
approved for human use in the United States. The focus in this unit will be given to the
basic mechanisms of contrast agents in MR without going into their clinical applications.
TECHNICAL DISCUSSION
Contrast Agents
Several paramagnetic contrast agents such as Gd-DTPA, albumin-Gd-DTPA, Gd-DTPA-
polylysine, and dysprosium-DTPA (Dy-DTPA) have been widely used in MRI. Param-
agnetic agents possess large magnetic moments, derived from their unpaired electrons,
because single unpaired electrons have magnetic dipole moments 657 times larger than
the magnetic dipole moment of a single, unpaired proton. In the absence of a paramagnetic
contrast agent, the relaxation mechanism of a spin results from the dipolar interactions
between nuclei as modulated by molecular rotational (tumbling) motion. In the presence
of paramagnetic ions, the interaction between the magnetic dipole of the water proton and
the magnetic dipole of the unpaired electron in the paramagnetic ion leads to T1 shorten-
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ing. In addition, the tumbling paramagnetic ions with their large magnetic moments
further augment the local magnetic variations experienced by the water protons, thereby
causing them to dephase more rapidly (shortened T2). The effects of paramagnetic contrast
agents are both concentration- and magnetic field–dependent.
The relaxivity and concentration of a contrast agent are the two factors determining its
effect on relaxation times. The relaxivity of a contrast agent can be defined as the change
in relaxation rate (∆Ri) per unit concentration of contrast agent while the concentration
is defined as the amount of contrast agent in a given volume. The relaxivities of the most
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Figure B6.4.1 T1 reduction effects of a contrast agent. (A) A single slice from a 3-D T1-weighted data
set before contrast agent was injected. (B) Image of the same slice after an intravenous injection of a
T1-shortening contrast agent. Since the T1 of blood is shortened, the blood vessels light up, and are
seen as bright spots in the image. Also, there is a loss of contrast between WM/GM because of the
larger blood volume content of GM (hence, its signal increases more than that of WM, reducing contrast).
(C) Subtraction of the first image from the second image depicts this signal increase predominantly in
the blood vessels, but also from the blood-containing tissue itself. Only those voxels with a positive
subtraction are shown; voxels with a negative subtraction are set to zero, leading to the isolated black
dots in this image. The imaging parameters used were (for panels A and B) TR/TE = 20 msec/6 msec,
θ = 25°, Ts = 5.12 msec, Nacq = 1, ∆x × ∆y × ∆z = 0.9 mm × 0.9 mm × 2.33 mm, Nx × Ny × Nz = 256 ×
224 × 60, τRF = 2.56 msec, Gss = 1.33 mT/m.
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commonly used agent, Gd-DTPA, have been found to be 4.5 liter/mmol/sec for K1 and
5.0 liter/mmol/sec for K2 in humans.
Consider a typical contrast-agent MR study where a single dose of Gd-DTPA (0.1
mmol/kg) is injected intravenously into an average adult with a body weight of ∼60 kg.
If we assume that the contrast agent is distributed evenly in the blood pool (∼5.5 kg), then
the concentration of the contrast agent is 1.1 mmol/liter. For inherent relaxation times of
1200 msec (T1,inherent) and 100 msec (T2,inherent) for venous blood, the effective relaxation
times can be shown to be reduced to 173 msec (T1,eff) and 65 msec (T2,eff) for this particular
concentration of the agent. Very quickly, much of the contrast agent is extravasated.
Several minutes later, the concentration will be much lower, and T1 values will signifi-
cantly increase (if the concentration, C, becomes 0.55 mM, T1 increases from 173 msec
to 302 msec).
The gadolinium ion (Gd3+), the basis of Gd-DTPA, has 7 unpaired electrons and thereby
possesses a very large magnetic moment. However, in its elementary form, this ion is
toxic. Although the toxicity is reduced by binding Gd3+ to chelates, the price to pay for
the reduced toxicity is the reduction in the number of binding sites available to water
protons. Although Gd-DTPA is an extravascular and extracellular contrast agent, for
normal brain imaging, it is confined in the vascular space by an intact blood-brain barrier.
A more recent contrast agent, Angiomark (EPIX), is the first gadolinium-based intravas-
cular contrast agent to progress to human trials. Angiomark, unlike currently available
extravascular and extracellular agents, binds strongly but reversibly to serum albumin in
plasma. Findings in vivo indicate a strong, persistent plasma T1 reduction with Angiomark
for 1 hr and a strong vascular enhancement on T1-weighted MR images (Lauffer et al.,
1998).
Relaxivity and contrast enhancement
In fast imaging, where TR is much less than T1, the signal for a 90° flip angle scan is
proportional to TR/T1 and, in this regime, tissues with shorter T1 have a higher signal than
tissues with longer T1, and the contrast is predominantly T1-weighted.
Certain external agents can be introduced into specific targeted tissues where these agents
act to reduce the T1 of that tissue. Figure B6.4.1 demonstrates the T1-shortening effect of
one of these agents. Suppose that the targeted tissue (in the case shown in Fig. B6.4.1,
the targeted tissue is blood) has similar NMR properties as its neighboring tissue, causing
an inability to differentiate the two using any of the three contrast mechanisms discussed
in UNIT B6.3, but contains a different signal response to the contrast agent. By delivering
the T1-shortening agent to the tissue of interest, the targeted signal is increased while the
signal from the background remains the same when a T1-weighted sequence is used. This
increases the contrast between the two tissues, and, for this reason, such agents are
commonly referred to as “contrast agents.”
In general, the increase in relaxation rate after T1 shortening is found to be directly
proportional to the concentration (C) of the contrast agent delivered to the tissue. If T1,0
is the intrinsic T1 of the tissue and T1(C) is its shortened value, it is found that:
where the constant of proportionality K1 is called the longitudinal relaxivity ( T1
relaxivity) with units of (mmol/liter)−1sec−1 (1 mmol/liter is also written as 1 mM;
millimolar), a property specific to the composition of the contrast agent. Figure B6.4.2A
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demonstrates the effect of a contrast agent in vivo on the T1 of blood for which T1,0 ≈
1200 msec at 1.5 T.
In addition to shortening the T1, these contrast agents also tend to shorten the T2 of the
tissue in a similar fashion to the T1 shortening, i.e.:
where K2 is the transverse relaxivity of the contrast agent. Figure B6.4.2B shows the effect
of contrast agent dosage on the T2 of blood (which has an intrinsic T2 ranging from 100
msec for venous blood to 200 msec for arterial blood). This concomitant decrease in T2
tends to partly counterbalance the effects of shortened T1. For many T1-shortening contrast
agents, the transverse and longitudinal relaxation rates are comparable in magnitude (K1
≈ K2). Since R2,0 > R1,0, a given increase in the concentration leads to a larger-magnitude
change in T1 and, hence, a larger-magnitude change in the signal due to this shortened T1
effect than due to the T2 reduction. It is only when K2C becomes comparable to R2,0 that
the signal loss due to the T2 shortening becomes significant and starts to overwhelm the
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Figure B6.4.2 T1 and T2 are plotted in (A) and (B), respectively, as functions of contrast agent
concentration delivered to the tissue of interest. The contrast agent is supposed to have longitudinal and
transverse relaxivities of 4.5 /mM/sec and 5.0 /mM/sec, respectively. Notice that the relative change in T1
for a given concentration is much larger than that for T2. (C) Blood signal in relative units as a function of
contrast agent concentration plotted for a spin echo acquisition with 600 msec TR and 20 msec TE (T1
and T2 of blood were taken to be 1200 msec and 150 msec, respectively). Note that, as the concentration
increases, the T2-reduction effect takes over and causes a reduction of blood signal. In essence, an optimal
concentration which maximizes the signal exists, in this case near 1 mM. 
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enhanced T1-weighted contrast. In fact, this cross-over point between signal loss due to
T2 shortening and signal increase due to T1 shortening defines an optimal contrast agent
dosage. New intravascular agents such as Angiomark (EPIX) tend to have a much higher
K1 (almost 25 /mM/sec) and K2 values similar to those of previous Gd-based agents.
A major clinical application of T1-shortening contrast agents, at present, is intended for
the improved detection of small lesions. Typically, lesions are best depicted in a T2-
weighted image before the contrast agent is injected. Despite being the most sensitive
contrast mechanism, it is not possible for the T2-weighted image to depict very small
lesions which are averaged with neighboring tissue of comparable NMR tissue properties.
The use of an intravenous injection of a T1 shortening agent is indicated for such patients
followed by a T1-weighted scan (preferably a short TE, short TR, high-resolution gradient-
echo scan). Most lesions are found to have a rich blood supply, and the enhanced signal
from the blood in the brain leads to improved lesion detection. Imaging of blood vessels
is also dramatically improved using a contrast agent (see Chapter B7).
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This article describes in detail the recent contrast agent, Angiomark.
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